EC Microbiology

Antibiotic resistance is an international communal wellbeing apprehension and occurs through several defined mechanisms. However, Pseudomonas species have been said to have genes that code for beta-lactamase production, some of such genes are SHV, CTX-M and AMPC. This study was aimed at detecting SHV, CTX-M and AMPC genes in multi-drug resistant Pseudomonas aeruginosa. The isolates were cultured on MacConkey agar and antibiotic sensitivity were done on Mueller-Hinton agar. Phenotypically identified was by Gram staining and biochemical testing. DNA extraction was carried out by boiling method and gene detection was done. Of the 135 Pseudomonas isolates studied, consequently, 81 (60%) of Pseudomonas spp isolates were multi-drug resistant. The distribution of the isolates by specimen revealed that, 32 (23.7%), 2 (1.5%), 37 (27.4%), 6 (4.4%), 2 (1.5%) and 2 (1.5%) were from urine, ear, wound, blood culture, abdominal fluid and pleural fluid respectively. Out of the six antibiotics used in this study, Ceftriaxone and Cefuroxime were the most resistant 75 (95.6%). The distribution of resistance genes showed that Molecular characterization with 16s rRNA markers revealed that some isolates that were phenotypically characterized as Pseudomonas spp whereas it was Alcaligenes faecalis. Conclusively, this study showed the presence of AmpC gene among Pseudomonas isolates from UPTH, thus patients can be treated effectively by the knowledge of the drug mechanism.

Keywords: SHV; CTX-M; AMPC; Multidrug Resistant Pseudomonas

1. Abraham EP and Chain E. “An enzyme from bacteria able to destroy penicillin”. Nature3 (1940): 713- 837.
2. Adékambi T., et al. “rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria”. Journal Clinical Microbiology12 (2003): 5699-5708.
3. Akanji BO., et al. “Genetic Fingerprinting of Pseudomonas aeruginosa involved in Nosocomial Infection as Revealed by RAPD-PCR Markers”. Biotechnology Journal1 (2011): 70-77.
4. Al-Dahmoshi HOM. “Genotypical and Phenotypic Investigation of Alginate Biofilm Formation among Pseudomonas aeruginosa Isolated from Burn Victims in Babylon, Iraq”. Science Journal of Microbiology (2013): 8.
5. Ali T., et al. “Characteristics and genetic diversity of multi-drug resistant extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from bovine mastitis”. Oncotarget52 (2017): 90144-90163.
6. Alsterlund R., et al. “Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak”. Infectious Diseases6-7 (2009): 410-415.
7. Ambler RP. “The structure of β-lactamases”. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences 289 (1980): 321-331.
8. Andrew JM. “Determination of minimum inhibitory concentrations”. Journal of Antimicrobial Chemotherapy 48 (2001): 5-16.
9. Banerjee D and Stableforth D. “The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way?” Drugs5 (2000): 1053-1064.
10. Birbrair A and Frenette PS. “Niche heterogeneity in the bone marrow”. Annals of the New York Academy of Sciences1 (2016): 82-96.
11. Borriss R., et al. “Relationship of Bacillus amyloliquefaciens clades associated with strains DSM 7T and FZB42T: a proposal for Bacillus amyloliquefaciens amyloliquefaciens subsp. nov. and Bacillus amyloliquefaciens subsp. plantarum subsp. nov. based on complete genome sequence comparisons”. International Journal Systemic Evolutionary Microbiology 61.8 (2011): 1786-1801.
12. Bush K., et al. “A functional classification scheme for β-lactamases and its correlation with molecular structure”. Antimicrobial Agents Chemotherapy 39 (1995): 1211-1233.
13. Bush K and Jacoby GA. “Updated functional classification of 𝛽-lactamases”. Antimicrobial Agents and Chemotherapy3 (2010): 969-976.
14. Cantὁn R., et al. “Prevalence and spread of extended-spectrum 𝛽-lactamase-producing Enterobacteriaceae in Europe”. Clinical Microbiology and Infection1 (2008): 144-153.
15. Chew KL., et al. “Klebsiella pneumoniae in Singapore: hypervirulent infections and the carbapenemase threat”. Frontiers in Cellular and Infection Microbiology 7 (2017): 13-23.
16. Ciˇzman M. “The use and resistance to antibiotics in the community”. International Journal of Antimicrobial Agents4 (2003): 297-307.
17. Cocolin L., et al. “Study of the ecology of fresh sausages and characterization of populations of lactic acid bacteria by molecular methods”. Applied Environmental Microbiology4 (2004): 1883-1894.
18. Dally S., et al. “DNA microarray for genotyping antibiotic resistance determinants in Acinetobacter baumannii clinical isolates”. Antimicrobial Agents and Chemotherapy10 (2013): 4761-4768.
19. D’Andrea MM Arena F., et al. “CTX-M-type 𝛽-lactamases: a successful story of antibiotic resistance”. International Journal of Medical Microbiology6-7 (2013): 305-317.
20. Davies J. “Inactivation of antibiotics and the dissemination of resistance genes”. Science5157 (1994): 375-382.
21. Didelot X., et al. “Transforming clinical microbiology with bacterial genome sequencing”. Nature Reviews Genetics9 (2012): 601-612.
22. Dietz H., et al. “The signal molecule for β-lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide”. Antimicrobial Agents Chemotherapy 41 (1997): 2113-2120.
23. Driscoll JA., et al. “The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections”. Drugs3 (2007): 351-368.
24. Empel J., et al. “Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex”. Journal Clinical Microbiology9 (2007): 2829-2834.
25. Euzéby JP. “List of Bacterial Names with Standing in Nomenclature: a folder available on the Internet”. International Journal Systemic Bacteriology Microbiology Society2 (1997): 590-592.
26. Fedarovich A., et al. “The role of the 𝛽5-𝛼11 loop in the active-site dynamics of acylated penicillin binding protein A from Mycobacterium tuberculosis”. Journal of Molecular Biology5 (2012): 316-330.
27. Felsenstein J. “Confidence limits on phylogenies: An approach using the bootstrap”. Evolution 39 (1985): 783-791.
28. Finch R., et al. “Antimicrobial Chemotherapy”. Oxford University Press (2012).
29. Fuentefria DB., et al. “Antibiotic-resistant Pseudomonas aeruginosa from hospital wastewater and superficial water. Are they genetically related?” Journal Environmental Management 92 (2011): 250-255.
30. Guasp C., et al. “Utility of internally transcribed 16S-23S rDNA spacer regions for the definition of Pseudomonas stutzeri genomovars and other Pseudomonas species”. International Journal Systematic Evolutionary Microbiology4 (2000): 1629-1639.
31. Höltje JV., et al. “The negative regulator of β-lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase”. FEMS Microbiology Letters 122 (1994): 159-164.
32. Hugenholtz P and Pace NR. “Identifying microbial diversity in the natural environment: a molecular phylogenetic approach”. Trends Biotechnology6 (1996): 190-197.
33. Jacobs C., et al. “Bacterial cell wall recycling provides cytosolic muropeptides as effectors for β-lactamase induction”. EMBO Journal 13 (1994): 4684-4694.
34. Jacobs C., et al. “AmpD, essential for both β-lactamase regulation and cell wall recycling, is a novel cytosolic N -acetylmuramyl-L-alanine amidase”. Molecular Microbiology 15 (1995): 553-559.
35. Jacobs C., et al. “Cytosolic intermediates for cell wall biosynthesis and degradation control inducible β-lactam resistance in gram-negative bacteria”. Cell 88 (1997): 823-832.
36. Jacoby GA and Munoz-Price LS. “The new beta-lactamases”. The New England Journal of Medicine4 (2005): 380-391.
37. Jamali S., et al. “Phenotypic and molecular characterization of cefotaximases, temoniera, and sulfhydryl variable β-lactamases in Pseudomonas and Acinetobacter isolates in an Indian tertiary health-care center”. Indian Journal of Pathology and Microbiology 60 (2017): 196-201.
38. Jemima SA and Verghese S. “Multiplex PCR for blaCTX-M and blaSHV in the extended spectrum beta lactamase (ESBL) producing Gram-negative isolates”. Indian Journal Medical Research 128 (2008): 313-317.
39. Jukes TH and Cantor CR. “Evolution of protein molecules”. In Munro HN, editor, Mammalian Protein Metabolism, Academic Press, New York (1969).
40. Khalil MA., et al. “Comparative study of virulence factors among ESβL-producing and nonproducing Pseudomonas aeruginosa clinical isolates”. Turkish Journal Medical Sciences1 (2015): 60-69.
41. Kim J., et al. “Occurrence of CTX-M-3, CTX-M-15, CTXM- 14, and CTX-M-9 extended-spectrum beta-lactamases in Enterobacteriaceae clinical isolates in Korea”. Antimicrobial Agents and Chemotherapy4 (2005): 1572-1575.
42. Klindworth A., et al. “Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies”. Nucleic Acids Research1 (2013): 1.
43. Korfmann G and Sanders CC. “ampG is essential for high-level expression of AmpC β-lactamase in Enterobacter cloacae”. Antimicrobial Agents and Chemotherapy 33 (1989): 1946-1951.
44. Levy SB. “Antibiotic resistance: consequences of inaction”. Clinical Infectious Diseases3 (2001): 124-129.
45. Levy SB. “Factors impacting on the problem of antibiotic resistance”. Journal of Antimicrobial Chemotherapy1 (2002): 25-30.
46. Li XZ and Nikaido H. “Efflux-mediated drug resistance in bacteria: an update”. Drugs12 (2009): 1555-1623.
47. Lodge J., et al. “Investigation of the Pseudomonas aeruginosa ampR gene and its role at the chromosomal ampC promoter”. FEMS Microbiology Letters 111 (1993): 315-320.
48. Lozupone CA and Knight R. “Global patterns in bacterial diversity”. Proceedings National Academy Sciences27 (2007): 11436-11440.
49. Maynard C., et al. “Antimicrobial resistance genes in enterotoxigenic Escherichia coli O149:K91 isolates obtained over a 23-year period from pigs”. Antimicrobial Agents and Chemotherapy 47 (2003): 3214-3221.
50. Meenaumari S., et al. “Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in an Indian Cardiac Hospital”. International Journal Engineering Science and Technology9 (2011): 7117-7124.
51. Mohammed EH., et al. “Spread of TEM, VIM, SHV, and CTX-M 𝛽-Lactamases in Imipenem-Resistant Gram-Negative Bacilli Isolated from Egyptian Hospitals”. International Journal of Microbiology3 (2016): 1-15.
52. Mohammed Y., et al. “Characterization of Extended-Spectrum Beta-lactamase from Escherichia coli and Klebsiella Species from North Eastern Nigeria”. Journal of Clinical and Diagnostic Research2 (2016): 7-10.
53. Naseer U and Sundsfjord A. “The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones”. Microbial Drug Resistance1 (2011): 83-97.
54. Niloufar Y., et al. “Recognition of the extended-spectrum-β-lactamases (ESBLS) amongst the gram-negative bacteria isolated from burn wound infection”. International Journal of Life Science and Pharma Research4 (2017): 30-35.
55. Nseir S., et al. “Pathophysiology of airway colonization in critically ill COPD patient”. Current Drug Targets 12 (2011): 514-520.
56. Ogbolu DO., et al. “CTX-M-15 is Established in Most Multidrug-Resistant Uropathogenic Enterobacteriaceae and Pseudomonaceae from Hospitals in Nigeria”. European Journal of Microbiology and Immunology1 (2018): 20-24.
57. Osman NAM., et al. “Molecular study of Panton-Valentine Leukocidin genes among Staphylococcus aureus clinical isolates in Khartoum State, Sudan”. American Journal Microbiology Research3 (2015):107-111.
58. Parija SC. Textbook of Microbiology and Immunology”. Elsevier Health Sciences (2014).
59. Piet JR., et al. “Meningococcal two-partner secretion systems and their association with outcome in patients with meningitis”. Infection and Immunity9 (2016): 2534-2540.
60. Pitout JDD. “Infections with extended-spectrum betalactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices”. Drugs3 (2010): 313-333.
61. Pitout JDD., et al. “Phenotypic and Molecular Detection of CTX-M-_-Lactamases Produced by Escherichia coli and Klebsiella spp”. Journal of Clinical Microbiology,12 (2004): 5715-5721.
62. Queenan AM., et al. “Effects of inoculum and 𝛽-Lactamase activity in AmpC- and Extended-Spectrum 𝛽-Lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology”. Journal of Clinical Microbiology1 (2004): 269-275.
63. Rahman S Ali., et al. “The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases”. BioMed Research International (2018): 1-14.
64. Randall LP., et al. “Prevalence of Escherichia coli carrying extended-spectrum 𝛽-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys in Great Britain between 2006 and 2009”. Journal of Antimicrobial Chemotherapy1 (2011): 86-95.
65. Robicsek A., et al. “qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States”. Antimicrobial Agents and Chemotherapy 50 (2006): 2872-2874.
66. Sahar A., et al. “Distribution of the blaOXA, blaVEB-1, and blaGES-1 genes and resistance patterns of ESBL-producing Pseudomonas aeruginosa isolated from hospitals in Tehran and Qazvin, Iran”. Revista da Sociedade Brasileira de Medicina Tropical3 (2017): 315-320.
67. Saitou N and Nei M. “The neighbor-joining method: A new method for reconstructing phylogenetic trees”. Molecular Biology and Evolution 4 (1987): 406-425.
68. Samaha-Kfoury JN and Araj GF. “Recent developments in 𝛽 lactamases and extended spectrum 𝛽 lactamases”. British Medical Journal7425 (2003): 1209-1213.
69. Sanders CC and Sanders WEJr. “β-Lactam resistance in gram-negative bacteria: global trends and clinical impact”. Clinical Infectious Diseases 15 (1992): 825-839.
70. Tawfik AF., et al. “Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia”. Microbial Drug Resistance3 (2011): 383-388.
71. UR Rahman SJ and Arenas H. “The polypeptide transport-associated (POTRA) domains of TpsB transporters determine the system specificity of two-partner secretion systems”. The Journal of Biological Chemistry28 (2014): 19799-19809.
72. Vandepitte J., et al. Basic laboratory procedures in clinical bacteriology: World Health Organization 2018 (2003).
73. Wayne PA. “Clinical Laboratory Standards Institute”. Performance Standards for Antimicrobial Susceptibility Testing: Twenty Fifth Informational Supplement, M100-S25. USA: C.L.S.I (2015).
74. Wieser A., et al. “MALDI-TOF MS in microbiological diagnostics identification of microorganisms and beyond (mini review)”. Applied Microbiology Biotechnology3 (2012): 965-974.
75. Wright AJ. “The penicillins”. Mayo Clinic Proceedings3 (1999): 290-307.
76. Yang L., et al. “Evolutionary dynamics of bacteria in a human host environment”. Proceedings National Academy Sciences U S A 108 (2011): 7481-7486.
77. Zeynudin A., et al. “Prevalence and antibiotic susceptibility pattern of CTX-M type extended-spectrum β-lactamases among clinical isolates of gram-negative bacilli in Jimma, Ethiopia”. BMC Infectious Diseases524 (2018): 1-10.
78. Zhao WH and Hu ZQ. “Epidemiology and genetics of CTXM extended-spectrum 𝛽-lactamases in Gram-negative bacteria”. Critical Reviews in Microbiology1 (2013): 79-101.
79. Zhou TC and Zhong JJ. “Production of validamycin A from hemicellulose hydrolysate by Streptomyces hygroscopicus 5008”. Bioresource Technology 175 (2015): 160-166.
80. Zongo KJ., et al. “First detection of bla TEM, SHV and CTX-M among Gram negative bacilli exhibiting extended spectrum β- lactamase phenotype isolated at University Hospital Center, Yalgado Ouedraogo, Ouagadougou, Burkina Faso”. African Journal of Biotechnology14 (2015): 1174-1180.